Stay updated on OpRegen Safety & Efficacy in Advanced Dry AMD Clinical Trial
Sign up to get notified when there's something new on the OpRegen Safety & Efficacy in Advanced Dry AMD Clinical Trial page.

Latest updates to the OpRegen Safety & Efficacy in Advanced Dry AMD Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check45 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check52 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check67 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check74 days agoChange DetectedThe website has added a new type of intervention and updated to revision v2.14.0, while removing the previous type of intervention and reverting to revision v2.13.3.SummaryDifference1%
- Check88 days agoChange DetectedThe website has updated its eligibility criteria for a study on dry age-related macular degeneration (AMD), with new additions including specific health requirements and clarifications on medical history, while also removing previous criteria that were similar.SummaryDifference4%
Stay in the know with updates to OpRegen Safety & Efficacy in Advanced Dry AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OpRegen Safety & Efficacy in Advanced Dry AMD Clinical Trial page.